Head-to-Head: which obesity drug wins for fat loss and heart health?

NCT ID NCT07589322

Recruiting now Disease control Sponsor: Tri-Service General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study directly compares two popular weight-loss medications, tirzepatide and semaglutide, in 120 adults with obesity and metabolic syndrome. Participants will be randomly assigned to one drug and monitored for 12 months using advanced body scans, blood tests, and AI analysis to see which drug works better for weight loss, fat reduction, and improving metabolic health. The goal is to find the most effective treatment for managing obesity and related health risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY AND METABOLIC SYNDROME

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tri-Service General Hospital
RECRUITING

Taipei, 114202, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••